Crossref
Nab-paclitaxel is a valuable NSCLC therapy option
The Journal of Community and Supportive Oncology · 2013
DOI: 10.12788/j.cmonc.0042 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Community and Supportive Oncology, 2013. Verfasst von Charu Aggarwal.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Aggarwal, C. (2013). Nab-paclitaxel is a valuable NSCLC therapy option. The Journal of Community and Supportive Oncology. https://doi.org/10.12788/j.cmonc.0042
Vancouver
Aggarwal C. Nab-paclitaxel is a valuable NSCLC therapy option. The Journal of Community and Supportive Oncology. 2013. doi:10.12788/j.cmonc.0042
BibTeX
@article{Aggarwal2013,
author = {Aggarwal, Charu},
title = {Nab-paclitaxel is a valuable NSCLC therapy option},
journal = {The Journal of Community and Supportive Oncology},
year = {2013},
doi = {10.12788/j.cmonc.0042}
}
EUVIMED